239 related articles for article (PubMed ID: 29982712)
1. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
Verstappen GM; Moerman RV; van Nimwegen JF; van Ginkel MS; Bijzet J; Mossel E; Vissink A; Hazenberg BPC; Arends S; Kroese FGM; Bootsma H
Rheumatology (Oxford); 2018 Oct; 57(10):1812-1821. PubMed ID: 29982712
[TBL] [Abstract][Full Text] [Related]
2. Salivary free light chains and salivary immunoglobulins as potential non-invasive biomarkers in primary Sjögren's syndrome.
Sandhya P; Kabeerdoss J; Christudoss P; Arulraj R; Mandal SK; Janardana R; Chebbi PP; Ganesan MP; Mahasampath G; Danda D
Int J Rheum Dis; 2022 Jan; 25(1):61-69. PubMed ID: 34791797
[TBL] [Abstract][Full Text] [Related]
3. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
Gottenberg JE; Aucouturier F; Goetz J; Sordet C; Jahn I; Busson M; Cayuela JM; Sibilia J; Mariette X
Ann Rheum Dis; 2007 Jan; 66(1):23-7. PubMed ID: 16569685
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjögren's syndrome: a pilot study.
Sandhya P; Christudoss P; Kabeerdoss J; Mandal SK; Aithala R; Mahasampath G; Job V; Danda D
Int J Rheum Dis; 2017 Jun; 20(6):760-766. PubMed ID: 28036132
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
6. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.
Gottenberg JE; Seror R; Miceli-Richard C; Benessiano J; Devauchelle-Pensec V; Dieude P; Dubost JJ; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Le Guern V; Morel J; Perdriger A; Puéchal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Nocturne G; Ravaud P; Mariette X
PLoS One; 2013; 8(5):e59868. PubMed ID: 23717383
[TBL] [Abstract][Full Text] [Related]
8. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
Jülich M; Kanne AM; Sehnert B; Budweiser S; Voll RE; Kollert F
Clin Rheumatol; 2018 Sep; 37(9):2361-2366. PubMed ID: 29858711
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
De Vita S; Gandolfo S; Zandonella Callegher S; Zabotti A; Quartuccio L
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):150-156. PubMed ID: 30156548
[TBL] [Abstract][Full Text] [Related]
10. Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma.
Cui L; Elzakra N; Xu S; Xiao GG; Yang Y; Hu S
Oncotarget; 2017 May; 8(18):30039-30049. PubMed ID: 28404907
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
12. Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?
Sudzius G; Mieliauskaite D; Siaurys A; Viliene R; Butrimiene I; Characiejus D; Dumalakiene I
Rheumatol Int; 2014 Feb; 34(2):235-41. PubMed ID: 24166212
[TBL] [Abstract][Full Text] [Related]
13. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
[TBL] [Abstract][Full Text] [Related]
14. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
15. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome.
Traianos EY; Locke J; Lendrem D; Bowman S; Hargreaves B; Macrae V; ; Tarn JR; Ng WF
Rheumatol Int; 2020 Apr; 40(4):541-548. PubMed ID: 32047959
[TBL] [Abstract][Full Text] [Related]
16. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
[TBL] [Abstract][Full Text] [Related]
17. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
19. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
20. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
